• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Commun . Microbial dynamics and pulmonary immune responses in COVID-19 secondary bacterial pneumonia

tetano

Editor, Senior Moderator
Nat Commun


. 2024 Oct 29;15(1):9339.
doi: 10.1038/s41467-024-53566-x. Microbial dynamics and pulmonary immune responses in COVID-19 secondary bacterial pneumonia

Natasha Spottiswoode[SUP] #[/SUP][SUP] 1 [/SUP], Alexandra Tsitsiklis[SUP] #[/SUP][SUP] 1 [/SUP], Victoria T Chu[SUP] 2 3 [/SUP], Hoang Van Phan[SUP] 1 [/SUP], Catherine DeVoe[SUP] 1 [/SUP], Christina Love[SUP] 1 [/SUP], Rajani Ghale[SUP] 1 4 [/SUP], Joshua Bloomstein[SUP] 5 [/SUP], Beth Shoshana Zha[SUP] 4 [/SUP], Cole P Maguire[SUP] 6 [/SUP], Abigail Glascock[SUP] 3 [/SUP], Aartik Sarma[SUP] 4 [/SUP], Peter M Mourani[SUP] 7 [/SUP], Katrina L Kalantar[SUP] 8 [/SUP], Angela Detweiler[SUP] 3 [/SUP], Norma Neff[SUP] 3 [/SUP], Sidney C Haller[SUP] 4 [/SUP]; COMET Consortium; Joseph L DeRisi[SUP] 3 9 [/SUP], David J Erle[SUP] 4 10 11 [/SUP], Carolyn M Hendrickson[SUP] 4 [/SUP], Kirsten N Kangelaris[SUP] 12 [/SUP], Matthew F Krummel[SUP] 13 [/SUP], Michael A Matthay[SUP] 4 [/SUP], Prescott G Woodruff[SUP] 4 11 [/SUP], Carolyn S Calfee[SUP] 4 [/SUP], Charles R Langelier[SUP] 14 15 [/SUP]



Collaborators, Affiliations
Abstract

Secondary bacterial pneumonia (2°BP) is associated with significant morbidity following respiratory viral infection, yet remains incompletely understood. In a prospective cohort of 112 critically ill adults intubated for COVID-19, we comparatively assess longitudinal airway microbiome dynamics and the pulmonary transcriptome of patients who developed 2°BP versus controls who did not. We find that 2°BP is significantly associated with both mortality and corticosteroid treatment. The pulmonary microbiome in 2°BP is characterized by increased bacterial RNA mass and dominance of culture-confirmed pathogens, detectable days prior to 2°BP clinical diagnosis, and frequently also present in nasal swabs. Assessment of the pulmonary transcriptome reveals suppressed TNFα signaling in patients with 2°BP, and sensitivity analyses suggest this finding is mediated by corticosteroid treatment. Further, we find that increased bacterial RNA mass correlates with reduced expression of innate and adaptive immunity genes in both 2°BP patients and controls. Taken together, our findings provide fresh insights into the microbial dynamics and host immune features of COVID-19-associated 2°BP, and suggest that suppressed immune signaling, potentially mediated by corticosteroid treatment, permits expansion of opportunistic bacterial pathogens.


 
Back
Top Bottom